Welcome to LookChem.com Sign In|Join Free
  • or
N1-[3-(Trifluoromethoxy)phenyl]acetamide is a chemical compound with the molecular formula C9H8F3NO2. It is an amide derivative, characterized by the presence of a carbonyl group (C=O) bonded to an amino group (NH2). The compound features a trifluoromethoxy group (CF3O-) attached to the 3-position of a phenyl ring, which is further connected to an acetamide group (CH3-CO-NH-). This molecule is known for its potential applications in pharmaceuticals and agrochemicals, particularly as a building block for the synthesis of various active ingredients. Its unique structure, with the trifluoromethoxy group, may contribute to its biological activity and selectivity, making it a subject of interest in the development of new drugs and pesticides.

1956-85-0

Post Buying Request

1956-85-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1956-85-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1956-85-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,9,5 and 6 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1956-85:
(6*1)+(5*9)+(4*5)+(3*6)+(2*8)+(1*5)=110
110 % 10 = 0
So 1956-85-0 is a valid CAS Registry Number.

1956-85-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[3-(trifluoromethoxy)phenyl]acetamide

1.2 Other means of identification

Product number -
Other names Acetamide,N-[3-(trifluoromethoxy)phenyl]

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1956-85-0 SDS

1956-85-0Relevant academic research and scientific papers

Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis

Huang, Zhenhua,Li, Heran,Zhang, Qian,Lu, Fangzheng,Hong, Mei,Zhang, Zhigang,Guo, Xiaocui,Zhu, Yuanju,Li, Sanming,Liu, Hongzhuo

supporting information, p. 1142 - 1147 (2017/11/15)

Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF. Here, we report novel indolinone-based multikinase inhibitors that target angiogenesis and fibrosis pathways and may serve as potential therapeutics for IPF. KBP-7018 is a novel, tyrosine kinase-selective inhibitor with potent effects on three fibrotic kinases (c-KIT, PDGFR, and RET). The pharmacokinetics (PK) properties of KBP-7018 were favorable in mice, rats, and dogs. In a bleomycin (BLM)-induced mouse pulmonary fibrosis model, 10, 30, and 100 mg/kg daily doses (q.d.) of KBP-7018 improved the 28-day survival rate in a dose-dependent manner. The improved efficacy of KBP-7018 compared to nintedanib provided a certain level of chemical validation for the involvement of PDGFR, c-KIT, and RET in IPF. Thus, KBP-7018 represents a novel multikinase inhibitor with differentiated activity, highly enhanced selectivity, and acceptable PK profiles that will enter phase I clinical trials.

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5

Herbert, Mark R.,Siegel, Dana L.,Staszewski, Lena,Cayanan, Charmagne,Banerjee, Urmi,Dhamija, Sangeeta,Anderson, Jennifer,Fan, Amy,Wang, Li,Rix, Peter,Shiau, Andrew K.,Rao, Tadimeti S.,Noble, Stewart A.,Heyman, Richard A.,Bischoff, Eric,Guha, Mausumee,Kabakibi, Ayman,Pinkerton, Anthony B.

scheme or table, p. 5718 - 5721 (2010/11/05)

Optimization of a screening hit from uHTS led to the discovery of TGR5 agonist 32, which was shown to have activity in a rodent model for diabetes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1956-85-0